Trade

Watchlist

Portfolio

Message

Set Alert

BSE LIVE NSE LIVE 26 Aug, 2025 12:21 Volume Todays L/H More ×

The shares of Biocon dropped 3 percent on December 8 as analysts cautioned investors about equity dilution after the company fully acquires its subsidiary Biocon Biologics.

The shares of the company closed at Rs 381.60 apiece on Monday, the lowest level seen by the stock in over three weeks.

Biocon on December 6 announced that its board has considered and approved the plan to acquire the remaining 23.3 percent equity stake in Biocon Biologics, to make it the pharma giant's 100 percent wholly-owned subsidiary. The shares will be bought from Mylan, Serum Institute Life Sciences, Tata Capital Growth Fund II and Activ Pine LLP.

The company added that the boa

See Full Page